PubMed

Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not.

Raun K, von Voss P, Gotfredsen CF, Golozoubova V, Rolin B, Knudsen LB.

Diabetes. 2007 Jan;56(1):8-15.PMID: 17192459 [PubMed - indexed for MEDLINE]Related articlesFree article

The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes.

Harder H, Nielsen L, Tu DT, Astrup A.

Diabetes Care. 2004 Aug;27(8):1915-21.PMID: 15277417 [PubMed - indexed for MEDLINE]Related articlesFree article

Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats.

Larsen PJ, Fledelius C, Knudsen LB, Tang-Christensen M.

Diabetes. 2001 Nov;50(11):2530-9.PMID: 11679431 [PubMed - indexed for MEDLINE]Related articlesFree article

Liraglutide, a once-daily human glucagon-like peptide-1 analog, minimizes food intake in severely obese minipigs.

Raun K, von Voss P, Knudsen LB.

Obesity (Silver Spring). 2007 Jul;15(7):1710-6.PMID: 17636089 [PubMed - indexed for MEDLINE]Related articles

The once-daily human GLP-1 analog, liraglutide, reduces olanzapine-induced weight gain and glucose intolerance.

Lykkegaard K, Larsen PJ, Vrang N, Bock C, Bock T, Knudsen LB.

Schizophr Res. 2008 Aug;103(1-3):94-103. Epub 2008 Jun 25.PMID: 18579346 [PubMed - indexed for MEDLINE]Related articles

Increased energy expenditure contributes more to the body weight-reducing effect of rimonabant than reduced food intake in candy-fed wistar rats.

Herling AW, Kilp S, Elvert R, Haschke G, Kramer W.

Endocrinology. 2008 May;149(5):2557-66. Epub 2008 Feb 14.PMID: 18276749 [PubMed - indexed for MEDLINE]Related articlesFree article

Incretin receptors for glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide are essential for the sustained metabolic actions of vildagliptin in mice.

Flock G, Baggio LL, Longuet C, Drucker DJ.

Diabetes. 2007 Dec;56(12):3006-13. Epub 2007 Aug 23.PMID: 17717280 [PubMed - indexed for MEDLINE]Related articlesFree article

GLP-1 derivative liraglutide in rats with beta-cell deficiencies: influence of metabolic state on beta-cell mass dynamics.

Sturis J, Gotfredsen CF, Rømer J, Rolin B, Ribel U, Brand CL, Wilken M, Wassermann K, Deacon CF, Carr RD, Knudsen LB.

Br J Pharmacol. 2003 Sep;140(1):123-32. Epub 2003 Jul 29.PMID: 12967942 [PubMed - indexed for MEDLINE]Related articlesFree article

Combination of the insulin sensitizer, pioglitazone, and the long-acting GLP-1 human analog, liraglutide, exerts potent synergistic glucose-lowering efficacy in severely diabetic ZDF rats.

Larsen PJ, Wulff EM, Gotfredsen CF, Brand CL, Sturis J, Vrang N, Knudsen LB, Lykkegaard K.

Diabetes Obes Metab. 2008 Apr;10(4):301-11.PMID: 18333889 [PubMed - indexed for MEDLINE]Related articles

Acute and chronic effects of the incretin enhancer vildagliptin in insulin-resistant rats.

Burkey BF, Li X, Bolognese L, Balkan B, Mone M, Russell M, Hughes TE, Wang PR.

J Pharmacol Exp Ther. 2005 Nov;315(2):688-95. Epub 2005 Jul 18.PMID: 16027230 [PubMed - indexed for MEDLINE]Related articlesFree article

7-But-2-ynyl-9-(6-methoxy-pyridin-3-yl)-6-piperazin-1-yl-7,9-dihydro-purin-8-one is a novel competitive and selective inhibitor of dipeptidyl peptidase IV with an antihyperglycemic activity.

Yamazaki K, Yasuda N, Inoue T, Nagakura T, Kira K, Shinoda M, Saeki T, Tanaka I.

J Pharmacol Exp Ther. 2006 Dec;319(3):1253-7. Epub 2006 Sep 15.PMID: 16980568 [PubMed - indexed for MEDLINE]Related articlesFree article

Inhibition of dipeptidyl peptidase-4 by vildagliptin during glucagon-like Peptide 1 infusion increases liver glucose uptake in the conscious dog.

Edgerton DS, Johnson KM, Neal DW, Scott M, Hobbs CH, Zhang X, Duttaroy A, Cherrington AD.

Diabetes. 2009 Jan;58(1):243-9. Epub 2008 Oct 7.PMID: 18840785 [PubMed - indexed for MEDLINE]Related articlesFree article

Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 reduces food intake and weight gain but maintains energy expenditure in diet-induced obese mice.

Wang SJ, Birtles S, de Schoolmeester J, Swales J, Moody G, Hislop D, O'Dowd J, Smith DM, Turnbull AV, Arch JR.

Diabetologia. 2006 Jun;49(6):1333-7. Epub 2006 Apr 13.PMID: 16612591 [PubMed - indexed for MEDLINE]Related articles

Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance.

Rosenstock J, Foley JE, Rendell M, Landin-Olsson M, Holst JJ, Deacon CF, Rochotte E, Baron MA.

Diabetes Care. 2008 Jan;31(1):30-5. Epub 2007 Oct 18.PMID: 17947341 [PubMed - indexed for MEDLINE]Related articlesFree article

The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients.

Balas B, Baig MR, Watson C, Dunning BE, Ligueros-Saylan M, Wang Y, He YL, Darland C, Holst JJ, Deacon CF, Cusi K, Mari A, Foley JE, DeFronzo RA.

J Clin Endocrinol Metab. 2007 Apr;92(4):1249-55. Epub 2007 Jan 23.PMID: 17244786 [PubMed - indexed for MEDLINE]Related articlesFree article

Ciliary neurotrophic factorAx15 alters energy homeostasis, decreases body weight, and improves metabolic control in diet-induced obese and UCP1-DTA mice.

Blüher S, Moschos S, Bullen J Jr, Kokkotou E, Maratos-Flier E, Wiegand SJ, Sleeman MW, Mantzoros CS.

Diabetes. 2004 Nov;53(11):2787-96. Erratum in: Diabetes. 2005 Jan;54(1):296. Sleemann, Mark W [corrected to Sleeman, Mark W]. PMID: 15504958 [PubMed - indexed for MEDLINE]Related articlesFree article

The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion.

El-Ouaghlidi A, Rehring E, Holst JJ, Schweizer A, Foley J, Holmes D, Nauck MA.

J Clin Endocrinol Metab. 2007 Nov;92(11):4165-71. Epub 2007 Aug 14.PMID: 17698900 [PubMed - indexed for MEDLINE]Related articlesFree article

Novel glucagon-like peptide-1 (GLP-1) analog (Val8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) mice.

Green BD, Lavery KS, Irwin N, O'harte FP, Harriott P, Greer B, Bailey CJ, Flatt PR.

J Pharmacol Exp Ther. 2006 Aug;318(2):914-21. Epub 2006 Apr 28.PMID: 16648370 [PubMed - indexed for MEDLINE]Related articlesFree article

The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose.

Utzschneider KM, Tong J, Montgomery B, Udayasankar J, Gerchman F, Marcovina SM, Watson CE, Ligueros-Saylan MA, Foley JE, Holst JJ, Deacon CF, Kahn SE.

Diabetes Care. 2008 Jan;31(1):108-13. Epub 2007 Oct 1.PMID: 17909087 [PubMed - indexed for MEDLINE]Related articlesFree article

The role of vildagliptin in the management of type 2 diabetes mellitus.

Kleppinger EL, Helms K.

Ann Pharmacother. 2007 May;41(5):824-32. Epub 2007 Apr 24. Review.PMID: 17456545 [PubMed - indexed for MEDLINE]Related articles